Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of fi

Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King's Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today presented additional findings from the P

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King's Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proportion of patients achieved complete steroid withdrawal at week 48 with a KSQ-Lung score improvement in the 5.0 mg/kg efzofitimod treatment group (29.5%) vs placebo (14.4%) (p=0.0199

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr's common stock, each with an exercise price of $5.71 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on September 3, 2025, the effective date of the grants. These stock awards were granted as an inducement

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update. "With the recent completion of the last patient visit in our Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), we are on track to report topline data in mid-September," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "This upcoming readout represents a majo

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company's Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The Company expects to report topline results from this study in the third quarter of 2025. "Completing this first-ever global Phase 3 and largest interventional study conducted for patients with s

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index is a subset o

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced findings from an interim analysis of eight patients in the ongoing Phase 2 EFZO-CONNECT™ study evaluating its lead therapeutic candidate, efzofitimod, in patients with limited or diff

SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 11:00am EDTLocation: New York, NYFormat: Fireside Chat Conference: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS TakeawaysDate

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity. Treatment practices in the U.S. show approximately 75% of diagnosed pulmonary sarcoidosis patients require treatment with steroids. SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines fr

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

10-Q - aTYR PHARMA INC (0001339970) (Filer)

8-K - aTYR PHARMA INC (0001339970) (Filer)

SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)

8-K - aTYR PHARMA INC (0001339970) (Filer)

EFFECT - aTYR PHARMA INC (0001339970) (Filer)

8-K/A - aTYR PHARMA INC (0001339970) (Filer)

S-8 - aTYR PHARMA INC (0001339970) (Filer)

S-3 - aTYR PHARMA INC (0001339970) (Filer)

10-Q - aTYR PHARMA INC (0001339970) (Filer)

8-K - aTYR PHARMA INC (0001339970) (Filer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

4 - aTYR PHARMA INC (0001339970) (Issuer)

RBC Capital Mkts downgraded aTyr Pharma from Outperform to Sector Perform and set a new price target of $1.50

Wells Fargo downgraded aTyr Pharma from Overweight to Equal Weight and set a new price target of $1.00

H.C. Wainwright downgraded aTyr Pharma from Buy to Neutral

Leerink Partners downgraded aTyr Pharma from Outperform to Market Perform and set a new price target of $1.00

Cantor Fitzgerald downgraded aTyr Pharma from Overweight to Neutral

Leerink Partners initiated coverage of aTyr Pharma with a rating of Outperform and set a new price target of $16.00

Cantor Fitzgerald initiated coverage of aTyr Pharma with a rating of Overweight

Wells Fargo initiated coverage of aTyr Pharma with a rating of Overweight and set a new price target of $17.00

Jefferies initiated coverage of aTyr Pharma with a rating of Buy and set a new price target of $9.00

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, including leading rare disease product launches. She will serve as a member of the Company's executive leadership team, overseeing global commercial strategy and operations for the efzofitimod prog

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). "We are excited to welcome Eric Benevich to the Board of Directors," said Timothy P. Coughlin, Chairman of the Board of aTyr. "His extensive background bringing new products to market and the knowledge and experti

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Jayant Aphale, Ph.D., as Vice President, Technical Operations. Dr. Aphale will serve as a member of the Company's executive leadership team, overseeing manufacturing activities at contract development and manufacturing organizations and implementing strategies related to the continuous improvement of commercial manufacturing, supply chain management, process development of new products and product lif

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King's Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proportion of patients achieved complete steroid withdrawal at week 48 with a KSQ-Lung score improvement in the 5.0 mg/kg efzofitimod treatment group (29.5%) vs placebo (14.4%) (p=0.0199

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Publication in Science Translational Medicine validates efzofitimod's mechanism of action. Company to host conference call and webcast today, March 13th at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announc

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 13, 2025Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI00725a32705e4ee3b22d05

SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

SC 13G - aTYR PHARMA INC (0001339970) (Subject)

SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)